Heavy Alcohol Use Increases Liver Cancer Risk in Hepatitis B Patients with Cirrhosis
- Details
- Category: HBV Treatment
- Created on Wednesday, 24 April 2013 00:00
Heavy drinking can add to the already elevated likelihood that people with liver cirrhosis related to hepatitis B virus (HBV) infection will develop hepatocellular carcinoma (HCC), according to a study published in the April 2013 Journal of Hepatology.
EASL International Liver Congress Starts this Week in Amsterdam
- Details
- Category: HBV Treatment
- Created on Monday, 22 April 2013 00:00
The 
48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) kicks off this Wednesday, April 24, at the Amsterdam RAI congress center. HIVandHepatitis.com will be on site to provide breaking news and analysis starting later this week.
EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors
- Details
- Category: HCV Treatment
- Created on Wednesday, 15 May 2013 00:00
About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Created on Wednesday, 15 May 2013 00:00
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies
- Details
- Category: HCV Treatment
- Created on Friday, 10 May 2013 00:00
Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus (HCV) and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
More Articles...
- EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
- EASL 2013: Vaniprevir Boosts Interferon/Ribavirin Response Rate for Prior Non-Responders with Cirrhosis
- EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients
- EASL 2013: HCV Protease Inhibitor Simeprevir Pushes Triple Therapy Cure Rate Up to 80%
- EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients
- EASL 2013: Sofosbuvir + Interferon/Ribavirin Cures 90% of People with Hard-to-Treat HCV Genotypes
- EASL 2013: Daclatasvir + Asunaprevir + BMS-791352 Looks Promising as Interferon-free Combo
- EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- EASL 2013: Hep C Quad Regimens Quashed, but Some Components Go Forward
- EASL 2013: Second-generation Protease Inhibitor Faldaprevir Cures up to 80% of Genotype 1 Hepatitis C
- EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- EASL 2013: MK-5172 Boosts Interferon/Ribavirin Response Regardless of IL28B Status
- EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
- EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1
Web Design and Development by